Navidea, FDA settle on details for NAV5001 trials

08/22/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has reached an agreement with the FDA regarding special-protocol assessments for Phase III trials for Navidea's investigational imaging agent NAV5001. The agent targets the brain's dopamine transporters for distinguishing Parkinsonian syndromes with SPECT imaging. Navidea plans to begin the trials this year.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ